Date: 2015-01-08
Type of information: R&D agreement
Compound:
Company: Proteros biostructures (Germany) Bayer Pharma (Germany)
Therapeutic area: Cardiovascular diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 8, 2015, Proteros biostructures announced that they have entered into a drug discovery research collaboration with Bayer Pharma. The objective of the collaboration is to identify novel compounds for the treatment of cardiovascular diseases. Discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a 2 year period to meet predefined milestones, while Bayer would be responsible for further preclinical candidate optimization and clinical development. Proteros will receive R&D funding, downstream milestones, and royalties on sales of potential resulting commercial products. The program is based on Proteros\' structure-guided lead discovery platform which combines structure analysis, medicinal chemistry and other discovery technologies to drive potency, selectivity, and safety of novel lead compounds.
Financial terms:
Latest news:
